Payment Policy: Leveling of Emergency Room Services Reference Number: TX.PP.053 Product Types: ALL

Similar documents
Payment Policy: New Patient Reference Number: CC.PP.036 Product Types: ALL

Payment Policy: Clinical Validation of Modifer 25 Reference Number: CC.PP.013 Product Types: ALL

Payment Policy:Modifier to Procedure Code Validation: Payment Modifiers Reference Number: CC.PP.028

Payment Policy: Unbundled Professional Services Reference Number: CC.PP.043 Product Types: ALL

Payment Policy: Unbundled Surgical Procedures Reference Number: CC.PP.045 Product Types: ALL

Payment Policy: Code Editing Overview Reference Number: CC.PP.011 Product Types: ALL Effective Date: 01/01/2013 Last Review Date: 06/28/2018

Clinical Policy: Brand Name Override Reference Number: CP.PMN.22 Effective Date: Last Review Date: 02.18

Emergency Services INDIANA HEALTH COVERAGE PROGRAMS. Copyright 2017 DXC Technology Company. All rights reserved.

Clinical Policy: Request for Medically Necessary Drug Not on the PDL Reference Number: CP.PMN.16 Effective Date: Last Review Date: 11.

Clinical Policy: Cabozantinib (Cometriq, Cabometyx) Reference Number: CP.PHAR.111

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Sodium phenylbutyrate (Buphenyl) Reference Number: CP.PHAR.208

Clinical Policy: Belatacept (Nulojix) Reference Number: CP.PHAR.201 Effective Date: Last Review Date: Line of Business: Medicaid

Payment Policy: Status B Bundled Services Reference Number: CC.PP.046 Product Types: ALL

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Irinotecan Liposome (Onivyde) Reference Number: CP.PHAR.304 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Factor VIIa (Recombinant - NovoSeven RT) Reference Number: CP.PHAR.220

Clinical Policy: Eltrombopag (Promacta) Reference Number: CP.PHAR.180

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

South Carolina Statutes and Regulations

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Eliglustat (Cerdelga) Reference Number: CP.PHAR.153 Effective Date: 02/16

Description Irinotecan liposome injection (Onivyde ) is a topoisomerase inhibitor.

Profilnine is indicated for: Prevention and control of bleeding in patients with factor IX deficiency (hemophilia B).

DRAFT NCOIL OUT-OF-NETWORK BALANCE BILLING TRANSPARENCY MODEL ACT

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Definitions: As used in this Policy, the following terms have the meanings as set forth below:

Patient Credit and Collections Policy. Penn State Health Revenue Cycle

National Council of Insurance Legislators (NCOIL) OUT-OF-NETWORK BALANCE BILLING TRANSPARENCY MODEL ACT

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Cabazitaxel (Jevtana) Reference Number: CP.PHAR.316 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Belatacept (Nulojix) Reference Number: CP.PHAR.201 Effective Date: Last Review Date: 11.18

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Definitions: As used in this Policy, the following terms have the meanings as set forth below:

I. Purpose. Departments(s) and Committee(s) Affected:

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Naproxen Oral Suspension (Naprosyn) Reference Number: HIM.PA.130 Effective Date: Last Review Date: 11.18

Description Inotuzumab ozogamicin (Besponsa ) is a CD22-directed antibody-drug conjugate.

Clinical Policy: Ibandronate Oral (Boniva) Reference Number: CP.PMN.96 Effective Date: Last Review Date: 02.19

Clinical Policy: Ruxolitinib (Jakafi)

See Important Reminder at the end of this policy for important regulatory and legal information.

Notification of this Policy to our Patients and Community members

Clinical Policy: Hemin (Panhematin) Reference Number: CP.PHAR.181 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ofatumumab (Arzerra) Reference Number: CP.PHAR.306 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Suvorexant (Belsomra) Reference Number: CP.PMN.109 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ruxolitinib (Jakafi) Reference Number: CP.PHAR.98 Effective Date: Last Review Date: 02.18

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Guselkumab (Tremfya) Reference Number: CP.PHAR.364 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Paricalcitol Injection (Zemplar) Reference Number: CP.PHAR.270

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Tildrakizumab-asmn (Ilumya) Reference Number: CP.PHAR.386 Effective Date: Last Review Date: 08.18

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Temsirolimus (Torisel) Reference Number: CP.PHAR.324 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

RULES OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF TENNCARE CHAPTER COVERKIDS TABLE OF CONTENTS

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Acitretin (Soriatane) Reference Number: CP.PMN.40 Effective Date: Last Review Date: Line of Business: Medicaid

IC Chapter Healthy Indiana Plan 2.0

Description Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG).

114.6 CMR: DIVISION OF HEALTH CARE FINANCE AND POLICY MEDICAL SECURITY BUREAU

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ciclopirox (Penlac) Reference Number: CP.PMN.24 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Financial Assistance - Enterprise APPROVED BY: SENIOR VICE PRESIDENT, FINANCE, HEALTH SERVICES FORMULATED BY: SENIOR DIRECTOR, PATIENT ACCOUNTS

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

BERKSHIRE FACULTY SERVICES FINANCIAL ASSISTANCE POLICY

HEALTH CARRIER GRIEVANCE PROCEDURE MODEL ACT

See Important Reminder at the end of this policy for important regulatory and legal information.

POLICY AND PROCEDURE. SCOPE: Coordinated Care Health Plan (Plan) and Envolve Pharmacy Solution departments.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Etidronate (Didronel) Reference Number: CP.PMN.94 Effective Date: Last Review Date: 02.19

Clinical Policy: Budesonide (Uceris) Reference Number: CP.CPA.165 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Transcription:

Payment Policy: Leveling of Emergency Room Services Reference Number: TX.PP.053 Product Types: ALL Effective Date: 10/01/2017 Last Review Date: See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Policy Overview To encourage providers to direct patients to more appropriate care settings, the health plan has adopted a payment strategy that will provide lower levels of reimbursement for services indicating lower levels of complexity or severity rendered in the emergency room. The purpose of this policy is to define payment criteria for emergency room services to be used in making payment decisions and administering benefits. Application Physicians or other qualified health professionals. Policy Description The Federal Balanced Budget Act (BBA) of 1997 and the Medicaid statute has established the definition of an Emergency Medical Condition (EMC) as follows: A medical condition manifesting itself by acute symptoms of sufficient severity (including severe pain) such that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical attention to result in: Placing the health of the individual (or, with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy; Serious impairment of bodily functions; or Serious dysfunction of any body organ or part. The hospital s Emergency Medical Treatment and Labor Act (EMTALA) provides that a hospital with a dedicated emergency department must provide an appropriate medical screening examination to determine whether or not an emergency medical condition exists. The hospital must also provide stabilizing treatment or an appropriate transfer to a more appropriate setting. The purpose of the medical screening examination is to determine whether or not an emergency medical condition exists. Prior authorization is not required for emergency medical services. Nothing in this policy excludes the provider s responsibility to perform the medical screening examination. Reimbursement Page 1 of 5

The Center for Medicaid and Medicare Services (CMS) affords states the flexibility to independently develop reimbursement methodologies for the use of emergency department services for lower levels of complexity or severity. When a physician bills a level 4 (99284) or level 5 (99285) emergency room service, with a diagnosis indicating a lower level of complexity or severity, the health plan will reimburse the provider at a level 3 (99283) reimbursement rate. Utilization The health plan s claims processing system will use a coding algorithm strategy to automatically adjudicate emergency department claims based on the applicable ED claim category in accordance with the diagnosis code appearing on the claim. If the diagnosis code classification falls into a categorization indicating a lower level of complexity or severity, the claim will be paid at the Level 3 emergency department reimbursement level. Documentation Requirements The patient s primary discharge diagnosis should be billed in the first diagnosis position on the emergency room claim form. Coding and Modifier Information This payment policy references Current Procedural Terminology (CPT ). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2016, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from current 2016 manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this payment policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. Emergency Department Services-New or Established Patient Page 2 of 5

CPT/HCPCS Code Descriptor 99281 Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: - A problem focused history; - A problem focused examination; and - Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self-limited or minor. 99282 Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: - An expanded problem focused history; - An expanded problem focused examination; and - Medical decision making of low complexity. needs. Usually, the presenting problem(s) are of low to moderate severity. 99283 Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: - An expanded problem focused history; - An expanded problem focused examination; and - Medical decision making of moderate complexity. needs. Usually, the presenting problem(s) are of moderate severity. 99284 Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: - A detailed history; - A detailed examination; and - Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity, and require urgent evaluation by the physician, or other qualified health care professionals but do not pose an immediate significant threat to life or physiologic function. 99285 Emergency department visit for the evaluation and management of a patient, which requires these 3 key components within the constraints imposed by the urgency of the patient's clinical condition and/or mental status: - A comprehensive history; - A comprehensive examination; and - Medical decision making of high complexity. Page 3 of 5

CPT/HCPCS Code Descriptor needs. Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function Definitions Prudent Layperson One who possesses an average knowledge of health and medicine who believes an emergency situation exists that may cause 1) serious medical harm, or: 2) serious impairment of bodily function, or: 3) serious dysfunction of any bodily organ. References 1. Current Procedural Terminology (CPT ), 2016 2. Centers for Medicare and Medicaid Services, CMS Manual System and other CMS publications and services. Revision History 08/10/2017 Initial Policy Draft Created 08/28/2017 Removed non-emergent language and replaced with lower level of complexity or severity. Removed redundant PLP language in second paragraph. Important Reminder For the purposes of this payment policy, Health Plan means a health plan that has adopted this payment policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any other of such health plan s affiliates, as applicable. The purpose of this payment policy is to provide a guide to payment, which is a component of the guidelines used to assist in making coverage and payment determinations and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage and payment determinations and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable plan-level administrative policies and procedures. This payment policy is effective as of the date determined by Health Plan. The date of posting may not be the effective date of this payment policy. This payment policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this payment policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. Health Plan retains the right to change, amend or withdraw this payment policy, and additional payment policies may be developed and adopted as needed, at any time. This payment policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise Page 4 of 5

professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This payment policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this policy are independent contractors who exercise independent judgment and over whom Health Plan has no control or right of control. Providers are not agents or employees of Health Plan. This payment policy is the property of Centene Corporation. Unauthorized copying, use, and distribution of this payment policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services. Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this payment policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this payment policy. Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs should be reviewed prior to applying the criteria set forth in this payment policy. Refer to the CMS website at http://www.cms.gov for additional information. *CPT Copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. 2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 5 of 5